

**Stereocontrolled Solid-Phase Synthesis of a 90-Membered Library of Indoline-Alkaloid-like Polycyclics from an Enantioenriched Aminoindoline Scaffold\*\***

Zhonghong Gan, P. Thirupathi Reddy, Sophie Quevillon, Samuel Couve-Bonnaire, and Prabhat Arya\*

With growing interest in the use of small molecules<sup>[1]</sup> for dissecting protein–protein interactions<sup>[2]</sup> and for understanding signaling pathways, the need for developing combinatorial methods to obtain small molecules that have stereochemical and skeletal diversity has also grown.<sup>[3,4]</sup> Owing to their structural complexity and the diversity of their functional groups, natural products are a source of bioactive lead compounds, and it is highly likely that libraries of small molecules that also display these features would serve as valuable tools.<sup>[5]</sup>

We initiated a combinatorial chemistry program that is aimed at providing indoline-alkaloid-like complex polycyclic compounds in a high-throughput manner.<sup>[6]</sup> Indole and indoline alkaloids belong to an important family of bioactive natural products, and several of these derivatives (1–3, see Figure 1) exhibit various biological





Figure 1. Examples of bioactive indole and indoline alkaloids.

[\*] Dr. Z. Gan, Dr. P. T. Reddy, S. Quevillon, Dr. S. Couve-Bonnaire, Dr. P. Arya  
 Chemical Biology Program  
 Steacie Institute for Molecular Sciences  
 National Research Council of Canada  
 100 Sussex Drive, Ottawa, Ontario, K1A0R6 (Canada)  
 Fax: (+1) 613-952-0068  
 E-mail: prabhat.arya@nrc.ca  
 S. Quevillon, Dr. P. Arya  
 Department of Chemistry  
 University of Ottawa  
 10 Marie Curie, Ottawa, K1N 6N5 (Canada)

[\*\*] We sincerely thank Stuart Schreiber, Jared Shaw, and the DOS team members at the Broad Institute of Harvard and MIT for providing alkylsilyl-linker-based macrobeads and for their help in our solid-phase synthesis projects. This work was supported by a NRC genomics and health initiative program, special VP-NRC funds for chemical biology, the National Cancer Institute of Canada (NCIC), and the Canadian Institutes of Health Research (CIHR). Malgosia Daroszweska, Michael Barnes, and Don Leek are thanked for their technical support.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.


responses. An important milestone in our approach is the development of a practical, enantioselective synthesis of a functionalized aminoindoline scaffold, **4**, that could be further utilized in introducing skeletal diversity.<sup>[7]</sup> This scaffold is highly unique and comprises four orthogonal protecting groups. Our plan was to utilize the phenolic hydroxyl group as an immobilization site in solid-phase synthesis. The remaining three functional groups could further be used in complexity-generating, diversity-oriented reactions. As shown in Scheme 1, aminoindoline **4** could be easily con-



Scheme 1. Natural-product-like and indoline-alkaloid-like complex polycyclic compounds. P = protecting group, R = diverse functional groups.

verted into **5**, which comprises a conjugated carboxylate ester. Following the immobilization of **5** through the phenolic hydroxyl group on a solid support to give **6** and upon selective removal of the indoline protecting group, the substrate could then be coupled to an amino acid to give **7**. A key step in our approach is the formation of a six-membered ring by a stereoselective, conjugate hetero (e.g. aza)-Michael reaction. This could provide the indoline-alkaloid-like tricyclic derivative **8**, in which the diversity could easily be introduced at four sites. A six-membered ring-closure strategy that involves the trapping of the primary amine by a conjugated carboxylic ester could also provide a general method to the synthesis of cyclic  $\beta$ -amino acids.<sup>[8]</sup>

The enantioselective synthesis of aminoindoline derivative **13** is shown in Scheme 2. 5-Hydroxy-2-nitro-benzaldehyde (**9**) was converted into **10** in two steps that involve protection of the phenol and elongation of the carbon chain. Compound **10** was then subjected to an asymmetric amino-hydroxylation reaction to give compound **11** in 79% yield (>92% ee).<sup>[9]</sup> The aminoindoline **12** was obtained from **11** in several steps that involved 1) reduction of the carboxylate ester (70%), 2) benzoyl-protection of the primary alcohol (OBz, 88%), 3) tosylation of the secondary alcohol (OTs, 87%), 4) selective reduction of the nitro group, and 5) cyclization under mild basic conditions (75% for two steps). Finally, compound **13** was obtained from **12** in three steps by which the indoline nitrogen was protected (Teoc, 98%), the Cbz protecting group was removed under hydrogenation, and the benzylic amine was protected with an Alloc group (85% for two steps, see Scheme 2). The overall sequence is very clean and the desired aminoindoline **13** could be obtained in



**Scheme 2.** a) 1) MEMCl, DIPEA, 97%; 2)  $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{COOEt}$ , NaH, 94%; b) Sharpless aminohydroxylation, 79%; c) 1)  $\text{LiBH}_4$ , 70%; 2) BzCl, pyridine, 88%; 3) TsCl, DMAP, 87%; 4)  $\text{H}_2$ , Lindlar cat.; 5)  $\text{K}_2\text{CO}_3$ , THF, 75% for two steps; d) 1) TeocCl, pyridine, 98%; 2)  $\text{H}_2$ , 10% Pd/C, MeOH; 3) AllocCl, pyridine, 85% for two steps. MEM = Methoxyethoxymethyl, DIPEA = diisopropylethylamine, Cbz = carbobenzyloxy, Bz = benzyl, Ts = *p*-toluenesulfonyl, DMAP = 4-dimethylamino-pyridine, Teoc = (trimethylsilyl)ethoxycarbonyl, Alloc = Allyloxycarbonyl.


large quantities (5–10 g) in a short period. With a practical method in hand for this scaffold, the next step was to prepare **15**, a key starting material to explore the stereoselective, conjugate hetero-Michael approach.

Scheme 3 shows our model study to obtain a tricyclic derivative by use of a stereoselective, conjugate hetero-Michael approach as the key step. Conversion of **13** into the conjugated ester **14** required the removal of the protecting group at the primary alcohol (99%), oxidation of the alcohol to the aldehyde, followed by a Wittig chain extension (93% for two steps). In a test study, upon removal of the Teoc group, the indoline amine was coupled with the amino acid chloride to give *N*-Fmoc-protected derivative **15** (88% for two steps). Upon removal of the Fmoc group (20% piperidine), we were delighted that the six-membered ring formed under these mild conditions. The primary amine generated in situ was easily trapped by the conjugated carboxylate ester in a stereoselective manner to give the cyclic compounds **16** (major) and **17** (minor) in 96% overall yield ( $R^1 = \text{Me}$ , > 10:1 ratio of two diastereomers, 82% d.r. for the major product). The stereochemistry of the new stereogenic center was assigned by NMR spectroscopy studies. The ease of the asymmetric, conjugate hetero-Michael approach to yield the tricyclic product was a pleasant surprise and it opens a simple and very attractive approach to the synthesis of cyclic  $\beta$ -amino

acids. The stereochemical preference of this reaction is postulated by the proposed transition states (**18** and **19**) that may account for the attack of the nucleophile from the  $\beta$  face. The conjugate hetero-Michael reaction is highly reproducible and gives the desired cyclic product(s) upon use of different amino acid derivatives.

The model solid-phase synthesis is shown in Scheme 4. Compound **20** was obtained from **13** in a few steps to perform solid-phase synthesis. In our hands, this scaffold gave poor loading with the use of (4-methoxyphenyl)diisopropylsilyl-propyl polystyrene beads (50–100  $\mu\text{m}$ , loading 1.4  $\text{mmol g}^{-1}$ ).<sup>[10]</sup> At this stage, we decided to work with compound **21a**, in which a three-carbon spacer was introduced between the aromatic moiety and the primary alcohol group.<sup>[11]</sup> As expected, the loading of **21a** with commercially available silyl-linker-based beads and with the macrobeads (500–560  $\mu\text{m}$  loading 1.29  $\text{mmol g}^{-1}$ )<sup>[12,13]</sup> worked very well to give product **21b** (1.12  $\text{mmol g}^{-1}$ , 87% upon cleavage of the product from the macrobead support).

The next series of steps were then attempted on the solid support. The indoline amine was first deprotected of its Fmoc group and then coupled with the Fmoc-protected amino acid chloride (first diversity) to give the amino acid coupled product, **22**. Several attempts were then made to optimize the conditions for the solid-phase coupling reaction, and the use of collidine as a base gave the best results. The coupled product, **22**, was then treated with piperidine, and, as observed in the synthesis carried out in solution, we were pleased that the primary amine was trapped with the conjugated carboxylate ester to give the tricyclic derivative **23** during the removal of the Fmoc group. Once again, as with the solution-state synthesis, the in situ conjugate hetero-Michael reaction was highly reproducible in the solid phase. The mild conditions for this cyclization reaction are highly appealing and attractive to explore its potential in the generation of a molecule library. The stereochemical outcome of this reaction was found to be dependent upon the choice of the amino acid, and the ratio of the two diastereomers, **25** and **26**, varied from 5:1 to 1:1.<sup>[14]</sup> To complete the test sequence in the solid phase, **23** was then subjected to 1) an amide coupling reaction to introduce the second diversity, 2) removal of the Alloc protecting group to give the free amine, and 3) reaction with carboxylic acid chloride to introduce the third diversity and to give **24**. Finally, compounds **25** and **26** were obtained upon cleavage of the substrates from the support under



**Scheme 3.** a) 1)  $\text{K}_2\text{CO}_3$ , MeOH, 99%; 2) Dess–Martin periodinane; 3)  $\text{Ph}_3\text{P}=\text{CHCOOEt}$ , 93% for two steps; b) 1) TBAF; 2) Fmoc alanine chloride, pyridine, 88%; c) 20% piperidine, 96%. TBAF = tetra-*n*-butylammonium fluoride, Fmoc = 9-fluorenylmethoxycarbonyl.

